EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS ‐Lung 003 Study, Branch Number 28

Kosuke Hamai iD, Nobuhiro Kanaji iD, Naoki Watanabe iD, Nobuhisa Ishikawa iD, Sayaka Ueno, Takeshi Masuda iD, Noboru Hattori iD, Masahiro Yamasaki iD, Naoko Matsumoto, Masamoto Nakanishi, Nobukazu Fujimoto iD, Nagio Takigawa iD und 3 weitere

Thoracic Cancer · 2026-10 · 17 (20)

DOI: 10.1111/1759-7714.70399 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, online erschienen am 15.10.2026. Verfasst von Kosuke Hamai und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, JA Onomichi General Hospital, Hiroshima, Japan. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Lung Neoplasms, Lung Diseases, Interstitial, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) improve the prognosis of patients with previously treated non‐small cell lung cancer (NSCLC). However, the efficacy and safety of ICIs for patients with NSCLC complicated with interstitial pneumonia (IP) remain unknown. This study aimed to analyze patients with NSCLC and IP treated with ICIs and to investigate the efficacy and exacerbation frequency of ICI therapy.

Methods

We prospectively enrolled patients with NSCLC and IP at multiple centers and examined progression‐free survival (PFS) and overall survival (OS) using the Kaplan–Meier method.

Results

The median PFS was 5.8 months, and the median OS was 9.7 months. ICI‐related lung injury was observed in seven of the 19 patients (36.8%). Pneumonitis was observed in one of five patients with a usual interstitial pneumonia (UIP) pattern and in six of 14 patients with a non‐UIP pattern; however, there was no significant difference in onset frequency. Furthermore, we observed no significant difference in PFS between patients with and without ICI‐related pneumonitis (6.8 vs. 3.3 months, respectively; p = 0.826). OS tended to be shorter in patients with ICI‐related pneumonitis, but the difference was not significant (8.0 vs. 16.7 months, respectively; p = 0.172).

Conclusions

The use of ICIs in patients with NSCLC and IP produces long‐term responses in some cases; however, there is a high possibility of ICI‐related pneumonitis. In cases where the condition worsens, post‐treatment may be difficult, and the prognosis may be poor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsLung NeoplasmsLung Diseases, InterstitialCarcinoma, Non-Small-Cell LungHumansFemaleMaleAgedMiddle AgedProspective StudiesPrognosisAged, 80 and over

Stichwörter der Autor:innen

drug‐induced pneumonitisimmune checkpoint inhibitorsinterstitial pneumonialung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Respiratory Medicine, JA Onomichi General Hospital, Hiroshima, Japan.
  • Department of Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan.
  • Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kida-gun, Kagawa, Japan.
  • Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Respiratory Medicine, Hiroshima Red Cross Hospital and Atomic-Bomb Survivors Hospital, Hiroshima, Japan.
  • Department of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.

ORCID-Profile: Kosuke Hamai, Nobuhiro Kanaji, Naoki Watanabe, Nobuhisa Ishikawa, Takeshi Masuda, Noboru Hattori, Masahiro Yamasaki, Nobukazu Fujimoto, Nagio Takigawa, Kazuya Nishii

Zitieren

APA

Hamai, K., Kanaji, N., Watanabe, N., Ishikawa, N., Ueno, S., Masuda, T., Hattori, N., Yamasaki, M., Matsumoto, N., Nakanishi, M., Fujimoto, N., Takigawa, N., Nishii, K., Hotta, K., & Kiura, K. (2026). Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS ‐Lung 003 Study, Branch Number 28. Thoracic Cancer, 17(20). https://doi.org/10.1111/1759-7714.70399

Vancouver

Hamai K, Kanaji N, Watanabe N, Ishikawa N, Ueno S, Masuda T, et al. Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS ‐Lung 003 Study, Branch Number 28. Thoracic Cancer. 2026;17(20). doi:10.1111/1759-7714.70399

BibTeX
@article{Hamai2026,
  author = {Hamai, Kosuke and Kanaji, Nobuhiro and Watanabe, Naoki and Ishikawa, Nobuhisa and Ueno, Sayaka and Masuda, Takeshi and Hattori, Noboru and Yamasaki, Masahiro and Matsumoto, Naoko and Nakanishi, Masamoto and Fujimoto, Nobukazu and Takigawa, Nagio and Nishii, Kazuya and Hotta, Katsuyuki and Kiura, Katsuyuki},
  title = {Efficacy and Safety of Immune Checkpoint Inhibitors for Lung Cancer Complicated by Interstitial Pneumonia: The CS ‐Lung 003 Study, Branch Number 28},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {20},
  doi = {10.1111/1759-7714.70399}
}
Kostenlos starten →